Shares of diabetes kingpin Novo Nordisk (NYSE: NVO ) are down more than 10% to start the week after a weekend announcement that its new long-acting insulin products, Tresiba and Ryzodeg, were not approved by the Food and Drug Administration. Is this news really worth the $13 billion that investors have lopped off of the company's market cap this morning? In the following video, health care bureau chief Brenton Flynn runs through the story in more detail and discusses why Sanofi (NYSE: SNY ) and Eli Lilly (NYSE: LLY ) are the beneficiaries.
Should you swap from Novo Nordisk to Eli Lilly?
Very soon, Eli Lilly will see nearly $0.40 of every $1.00 in sales exposed to generic competition. How does the company plan to respond to this huge patent cliff? Better yet, what does this mean for investors? In a brand new premium report on Eli Lilly, The Motley Fool's top pharmaceuticals analyst delves into everything investors need to know about the stock today. Simply click here now to claim your copy.
RSS Headlines
Fool UK
Comments from our Foolish Readers
Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the
Report this Comment icon found on every comment.
Be the first one to comment on this article.